Table 5.

Impact of hematopoietic stem cell transplantation in for AML patients with extramedullary manifestations in ELN2017 groups

Survival times of EM AML patients according to ELN2017 groups	HCT	no HCT	Hazard ratio	Cox regression p-value
ELN2017 favorable	n = 20	n = 61
Event-free survival	13.5 [4.8-n.r.]	12.6 [7.8–27.5]	0.86 [0.45–1.65]	0.659
Relapse-free survival	29.0 [7.5-n.r.]	43.6 [12.6-n.r.]	1.35 [0.66–2.78]	0.410
Overall survival	54.0 [11.0-n.r.]	27.2 [13.6-n.r.]	0.81 [0.41–1.59]	0.537
ELN2017 intermediate	n = 22	n = 55
Event-free survival	9.1 [3.7–44.1]	3.6 [1.8–7.5]	0.55 [0.32–0.98]	0.043
Relapse-free survival	10.8 [4.6-n.r.]	8.4 [2.1–14.4]	0.69 [0.35–1.35]	0.277
Overall survival	44.1 [9.1-n.r.]	7.5 [3.6–13.1]	0.40 [0.21–0.77]	0.006
ELN2017 adverse	n = 23	n = 33
Event-free survival	7.4 [1.1–13.6]	1.2 [0.3–3.0]	0.48 [0.27–0.85]	0.013
Relapse-free survival	11.6 [4.2–44.0]	6.0 [2.3–9.8]	0.51 [0.24–1.08]	0.077
Overall survival	21.0 [13.6–48.4]	7.1 [3.1–9.2]	0.31 [0.17–0.58]	< 0.001

Survival times for AML patients harboring extramedullary manifestations (EM) are compared for patients receiving or not receiving hematopoietic stem cell transplantation (HCT). Survival times in months. Cox-proportional hazard models were used to obtain univariable hazard ratios. Brackets show 95%-confidence intervals. n.r. = not reached (due to small sample sizes and thus limited numbers of events within the ELN subgroups of EM AML patients who underwent HCT not all upper confidence interval limits can be estimated)